Instruction for use: Kasnol

Active substance: Bromhexine + Guaifenesin + Salbutamol + Racementhol

ATX Code R05CA Expectorant drugs

Pharmacotherapeutic group:

Beta-adrenergic agonist in combination

Sekretolitiki stimulants and motor function airways in combination

The nosological classification (ICD-10)

J18 Pneumonia without specifying the pathogen

Alveolar pneumonia, Community-acquired pneumonia is atypical, Community-acquired pneumonia nepnevmokokkovaya, Pneumonia, Inflammation of the lower respiratory tract, Inflammatory disease of the lungs, lobar pneumonia, Infections of the respiratory tract and lungs, Infections of the lower respiratory tract, Cough in inflammatory diseases of the lung and bronchus, lobar pneumonia, nosocomial pneumonia, Exacerbation of chronic pneumonia, Acute community-acquired pneumonia, Acute pneumonia, lobular pneumonia, Pneumonia abscessed, bacterial Pneumonia, lobar pneumonia, Pneumonia alopecia, Pneumonia with obstruction of sputum discharge, Pneumonia in AIDS patients, Pneumonia in Children, Septic pneumonia, Chronic obstructive pneumonia, Chronic pneumonia, Lymphoid interstitial pneumonia

J40 Bronchitis, not specified as acute or chronic

wheeze bronchitis, Allergic bronchitis, Bronchitis asthma, Rinotraheobronhit, Asthmatic bronchitis, Bacterial bronchitis, Bronchitis, Bronchitis smoker, Inflammation of the lower respiratory tract, bronchi disease, Qatar smoker, smokers Cough, Cough in inflammatory diseases of the lung and bronchus, Violation of bronchial secretions, Violation of the functions of the bronchi, Acute bronchitis, Subacute bronchitis, tracheobronchitis, Chronic lung disease

J43 Emphysema

Interstitial emphysema, Emphysema, Chronic lung disease, Chronic obstructive pulmonary disease, Obstructive pulmonary emphysema, Chronic pulmonary emphysema, Chronic obstructive pulmonary emphysema

J44 Other chronic obstructive pulmonary disease

Allergic bronchitis, Bronchitis asthma, Asthmatic bronchitis, wheeze bronchitis, Bronchitis is an obstructive, bronchi disease, Shortness of sputum in acute and chronic respiratory diseases, Cough in inflammatory diseases of the lung and bronchus, Reversible airflow obstruction, Reversible obstructive airway disease, Obstructive bronchitis disease, Obstructive lung disease, Obstructive bronchitis, Spastic bronchitis, Chronic lung disease, Chronic nonspecific lung diseases, Chronic obstructive pulmonary disease, Chronic obstructive bronchitis, Chronic obstructive airway disease, Chronic obstructive pulmonary disease, Restrictive lung pathology

J45 Asthma

Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma

J64 Pneumoconiosis unspecified

Pneumoconiosis, Pneumoconiosis caused by organic dust

R09.3 Sputum

Bronchial asthma with obstruction of sputum discharge, Isolation of viscous mucus, viscous mucus, sputum hyperproduction, Hypersecretion of bronchial glands, Thick mucus, Obstruction of the bronchi of the mucous plug, The difficulty sputum discharge, Shortness of sputum, Shortness of sputum in acute and chronic respiratory diseases, Difficult expectoration, Cough with difficult expectoration of viscous, Cough with difficult expectoration,increased sputum viscosity,Poor expectoration,Trudnootdelyaemoy viscous mucus,sputum, Trudnootdelyaemoy bronchial secretion, Trudnootdelyaemoy viscous secret, Inflammation of the upper respiratory tract illness with difficult sputum

Composition

5 ml syrup

active substance:

salbutamol sulphate 1 mg

bromhexine hydrochloride 2 mg

guaifenesin 50 mg

Menthol 0.5 mg

Excipients: sucrose; citric acid monohydrate; sodium edetate; sodium benzoate; potassium sorbate; propylene glycol; glycerol; A solution of 70% sorbitol; Ponceau 4R; raspberry flavor

Description

red liquid with raspberry odor and a sweet taste.

Pharmacological Properties
Pharmachologic effect

expectorant, mucolytic, bronchodilatory.

pharmacodynamics

Combination product consisting of the ingredients used for the symptomatic treatment of coughing in various lung diseases. It has a bronchodilator, mucolytic and expectorant action.

Salbutamol has a bronchodilator effect by selective action on the β2-adrenergic receptors of the bronchi.

Bromhexinum liquefies phlegm and increases its volume. Mucolytic effect is due to the ability to depolymerize and dilute mucoproteins and mucopolysaccharide fibers.

Gvayfenezin has expectorant action. It reduces the adhesiveness, the surface tension of sputum, which improves its expectoration.

Menthol has mild antiseptic properties, soothes and reduces irritation of the respiratory tract mucosa.

Indications

Acute and chronic bronchopulmonary diseases accompanied by difficulty sputum discharge (asthma, bronchitis, obstructive bronchitis, pneumonia, emphysema, pneumoconiosis, etc..).

Contraindications

Hypersensitivity to the drug;

tachycardia;

myocarditis;

heart defects;

decompensated diabetes;

hyperthyroidism;

glaucoma;

hepatic or renal failure;

gastric ulcer and duodenal ulcer in the acute stage;

sucrose deficit / isomaltose, fructose intolerance, glucose-galactose malabsorption (because the product contains sucrose and sorbitol);

pregnancy;

lactation;

Precautions: Patients with diabetes mellitus, hypertension, duodenal ulcer stomach in remission.

Pregnancy and breast-feeding

If necessary, drug treatment Kasnol® during lactation, breast-feeding should be discontinued.

Side effects

Sometimes there are headache, dizziness, increased nervous irritability, insomnia, somnolence, tremor, convulsions, nausea, vomiting, diarrhea, exacerbation of gastric ulcer and duodenal ulcers, heart palpitations, perhaps urine staining pink, allergic reactions (rash, urticaria ), decrease in blood pressure, collapse.

Interaction

Other β2-Adrenomimeticalkie funds and theophylline enhance the effect of salbutamol and increase the likelihood of side effects.

Kasnol® The drug is not prescribed concurrently with drugs containing codeine and other antitussive, as this makes it difficult attenuated sputum expectoration.

Part of the preparation Kasnol® bromhexine facilitates the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) in the lung tissue.

Not recommended for use Kasnol® drug simultaneously with non-selective blockers, β-adrenergic such as propranolol.

Part of the drug salbutamol Kasnol® not recommended for patients who receive MAO inhibitors.

Diuretics are drugs and corticosteroids enhance the hypokalemic effect of salbutamol.

Do not take simultaneously with the preparation Kasnol® alkaline water.

Dosing and Administration

Inside.

Adults and children over 12 years - 10 ml (2 tsp) 3 times a day; children up to 6 years old - 5 ml (1 teaspoon) 3 times a day; from 6 to 12 years - 10.5 ml (2.1 tsp), 3 times a day.

Between the use of regular doses of the drug requires a break of at least 6 hours.

Overdose

Symptoms of overdose have been reported. Perhaps increased above side effects.

Treatment: symptomatic.

release Form

Syrup. In 100 or 200 ml in a bottle of dark glass, sealed with a screw cap aluminum with control of the first opening and dimensional plastic cups ¹1; 1 fl. placed in a cardboard box.

Conditions of supply of pharmacies

On prescription.

Storage conditions

In the dark place at a temperature below 25 ° C.

Keep out of the reach of children.

The shelf life

3 years.

Do not use beyond the expiration date printed on the package.